TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33847856

Group type: EXPERIMENTAL
Intervention: 188Re-HEDP at 40 MBq/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 188Re-HEDP at 50 MBq/kg
Number of subjects: 54
Study: 34463814

Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated radiotherapy (RT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normofractionated radiotherapy (RT)
Number of subjects: 14
Study: 34780099

Group type: EXPERIMENTAL
Intervention: CAMS‐G
Number of subjects: 30

Group type: COMPARATOR
Intervention: CAU
Number of subjects: 30
Study: 36252151

Group type: EXPERIMENTAL
Intervention: Formula C (cannabidiol-rich preparation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (blinded)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Open-label active product (after crossover)
Number of subjects: 24
Study: 34880011

Group type: EXPERIMENTAL
Intervention: 4-week semisupervised resistance training programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (regular physical activity)
Number of subjects: 60
Study: 35428274

Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain (OKC) exercises
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain (CKC) exercises
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (education about clinical manifestations, risk factors, diagnosis, treatment, and nursing care for knee via printed materials)
Number of subjects: 66
Study: 32359094

Group type: EXPERIMENTAL
Intervention: Sex-stratified nomogram incorporating body compositions and clinical factors
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Low skeletal muscle index (myopenia), high intramuscular adipose tissue content (myosteatosis), and high visceral to subcutaneous adipose tissue area (adiposity)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 414
Study: 34558966

Group type: EXPERIMENTAL
Intervention: ExerCube (EX)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate endurance run (ER)
Number of subjects: 28
Study: 32284380

Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 1 g
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 0.25 to 8 g (single ascending doses)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 0.25 to 2 g (multiple ascending doses every 6 hours for 29 doses)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 1 g with SUL (1 g) and/or IMI-CIL (0.5/0.5 g)
Number of subjects: 124
Study: 35066737

Group type: EXPERIMENTAL
Intervention: Carvedilol-SR once a day
Number of subjects: 272

Group type: COMPARATOR
Intervention: Carvedilol-IR twice a day
Number of subjects: 272
Study: 33637122

Group type: EXPERIMENTAL
Intervention: StayBalanced balance training programme with close facilitation (support and close follow-ups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: StayBalanced balance training programme with access to the website only
Number of subjects: 0
Study: 32503608

Group type: EXPERIMENTAL
Intervention: YinQiSanHuang-antiviral decoction with entecavir
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo with entecavir
Number of subjects: 802
Study: 35748900

Group type: EXPERIMENTAL
Intervention: AI-CAD positive scores (≥ 10%)
Number of subjects: 500

Group type: COMPARATOR
Intervention: AI-CAD
Number of subjects: 500

Group type: COMPARATOR
Intervention: Experienced breast radiologist
Number of subjects: 500
Study: 32441353

Group type: COMPARATOR
Intervention: Trauma patients
Number of subjects: 37
Study: 35248012

Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 100
Study: 34295663

Group type: EXPERIMENTAL
Intervention: Docetaxel (37.5 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (DC group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (GC group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Previous literature anti-tumor therapy only group
Number of subjects: 52
Study: 32325794

Group type: EXPERIMENTAL
Intervention: Lactobacilli (L.) rhamnosus GR‐1 and L. reuteri RC‐14, 5 × 10^9 CFU, 2 capsules/day for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (both groups)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 40
Study: 36116393

Group type: EXPERIMENTAL
Intervention: Dilapan-S
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propess
Number of subjects: 0
Study: 33533901

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Number of subjects: 386

Group type: COMPARATOR
Intervention: Continued corticosteroids
Number of subjects: 386
Study: 33376176

Group type: EXPERIMENTAL
Intervention: Adjunct oral betamethasone for 2 days
Number of subjects: 700

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 700
Study: 32573808

Group type: EXPERIMENTAL
Intervention: Variable-angle endoscope (VAE)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fixed-angle endoscope (FAE)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lung ventilation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Endoscope type
Number of subjects: 5
Study: 33219115

Group type: EXPERIMENTAL
Intervention: Progressive tendon-loading exercises (PTLE)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Eccentric exercise therapy (EET)
Number of subjects: 76
Study: 32019557

Group type: EXPERIMENTAL
Intervention: Fluid restriction + low CVP (Group L)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fluid restriction (Group F)
Number of subjects: 140
Study: 34092381

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) program for eight weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study: 34407775

Group type: EXPERIMENTAL
Intervention: Healthy Pregnancy Service
Number of subjects: 49
Study: 33568491

Group type: EXPERIMENTAL
Intervention: Girl2Girl
Number of subjects: 948

Group type: COMPARATOR
Intervention: Control
Number of subjects: 948
Study: 36087588

Group type: EXPERIMENTAL
Intervention: 60 μg MenB-FHbp
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: 120 μg MenB-FHbp
Number of subjects: 796

Group type: COMPARATOR
Intervention: Control (HAV vaccine and saline)
Number of subjects: 796
Study: 34009435

Group type: EXPERIMENTAL
Intervention: Morning exercise
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Evening exercise
Number of subjects: 25

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 25
Study: 33884691

Group type: COMPARATOR
Intervention: HOB elevation to <30°
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HOB elevation to 30°
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HOB elevation to 45°
Number of subjects: 60
Study: 33939054

Group type: EXPERIMENTAL
Intervention: Group well child care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 175
Study: 32220375

Group type: EXPERIMENTAL
Intervention: Early post-operative feeding (consumption of solid food on POD1)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Early tolerance of solid food (consumption of at least half of three meals on POD1 or 2 without vomiting)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Provision of pre-operative bowel preparation
Number of subjects: 301

Group type: COMPARATOR
Intervention: Laparoscopic/laparoscopic assisted surgery
Number of subjects: 301
Study: 36184994

Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 120
Study: 32901830

Group type: EXPERIMENTAL
Intervention: Micro F IOL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: POD F IOL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: POD FT IOL
Number of subjects: 45

Group type: COMPARATOR
Intervention: All IOL models
Number of subjects: 45
Study: 35792365

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.80 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33515782

Group type: EXPERIMENTAL
Intervention: NOURISH-T+ intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 260
Study: 36287567

Group type: EXPERIMENTAL
Intervention: Finerenone (10 or 20 mg once daily)
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 32003275

Group type: EXPERIMENTAL
Intervention: Project ADHerence Education and Risk Evaluation (ADHERE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medication Adherence and Care Engagement (MACE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 35123419

Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning (ISCON) prior to esophagectomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning (ISCON)
Number of subjects: 20
Study: 33813569

Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 35252455

Group type: EXPERIMENTAL
Intervention: Acutreatment (n = 30)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham Acutreatment (placebo, n = 27)
Number of subjects: 57
Study: 32555144

Group type: EXPERIMENTAL
Intervention: Smartphone-based self-assessments for depression severity
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Smartphone-based self-assessments for mania severity
Number of subjects: 84
Study: 35115269

Group type: EXPERIMENTAL
Intervention: Female trainee (n = 50)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Male trainee (n = 57)
Number of subjects: 107
Study: 35750637

Group type: EXPERIMENTAL
Intervention: AdVEGF‐D gene therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 32681063

Group type: EXPERIMENTAL
Intervention: Music therapy (recorded maternal singing/heartbeat)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100
Study: 34928719

Group type: EXPERIMENTAL
Intervention: Patient Concerns Inventory intervention
Number of subjects: 368

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 368
Study: 34405233

Group type: EXPERIMENTAL
Intervention: Early-onset stage III colon adenocarcinoma (EO-CC)
Number of subjects: 35713
Study: 32796009

Group type: EXPERIMENTAL
Intervention: Delay in diabetes onset by 1 year
Number of subjects: 3058

Group type: EXPERIMENTAL
Intervention: Delay in diabetes onset by 9 years
Number of subjects: 3058
Study: 36129700

Group type: EXPERIMENTAL
Intervention: Structural Metascore (SMS) using HRT rim area, Cirrus OCT average RNFL thickness, and Spectralis OCT RNFL global thickness normalized on a scale of 0 to 100.
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Average grades assigned by clinicians based on structural measurement printouts alone.
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Average grades assigned by clinicians based on metascore plots alone.
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Average grades assigned by clinicians based on printouts + metascore plots.
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Average absolute predictive ability of the SMS.
Number of subjects: 1824
Study: 34587803

Group type: EXPERIMENTAL
Intervention: Robotic arm‐assisted bi‐unicompartmental knee arthroplasty (bi‐UKA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional mechanically aligned total knee arthroplasty (TKA)
Number of subjects: 76
Study: 32804308

Group type: EXPERIMENTAL
Intervention: Training in allocentric spatial updating
Number of subjects: 40

Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 40
Study: 35618953

Group type: EXPERIMENTAL
Intervention: Reparixin 1200 mg orally three times daily for up to 21 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 55
Study: 33848641

Group type: EXPERIMENTAL
Intervention: FLOW program implementation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Implementation-facilitation for FLOW program
Number of subjects: 9
Study: 35611778

Group type: EXPERIMENTAL
Intervention: 10Hz rTMS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 47
Study: 33621540

Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations ≤400 pg/mL
Number of subjects: 14737

Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations 400-999 pg/mL
Number of subjects: 14737

Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations 1000-1999 pg/mL
Number of subjects: 14737

Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations 2000-2999 pg/mL
Number of subjects: 14737

Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations ≥3000 pg/mL
Number of subjects: 14737

Group type: EXPERIMENTAL
Intervention: NT-proBNP plasma concentrations across groups
Number of subjects: 14737
Study: 32917002

Group type: EXPERIMENTAL
Intervention: Regular exercise (2 to 3 times per week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sedentary lifestyle (not exercising regularly)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 102
Study: 33217058

Group type: EXPERIMENTAL
Intervention: Ridge preservation with a xenogeneic bone substitute covered with a collagen matrix (CM-group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ridge preservation with a xenogeneic bone substitute covered with a free palatal graft (PG-group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Spontaneous healing (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CM-group vs PG-group
Number of subjects: 75
Study: 32058020

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study: 32153330

Group type: EXPERIMENTAL
Intervention: Reminder SMS
Number of subjects: 200

Group type: COMPARATOR
Intervention: No reminder SMS (Control)
Number of subjects: 200
Study: 34207523

Group type: EXPERIMENTAL
Intervention: Breastfeeding for ≥4 months
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Moderate or high levels of physical activity
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG) ≤9 kg
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Modifiable factor score (range 0-3)
Number of subjects: 667
Study: 33048053

Group type: EXPERIMENTAL
Intervention: Internet-based multimodal pain program
Number of subjects: 43

Group type: COMPARATOR
Intervention: Occlusal splint therapy (Control)
Number of subjects: 43
Study: 35352280

Group type: EXPERIMENTAL
Intervention: Erlotinib 75 mg QD plus ritonavir 200 mg QD
Number of subjects: 9

Group type: COMPARATOR
Intervention: Erlotinib 150 mg QD (control arm)
Number of subjects: 9
Study: 34140229

Group type: EXPERIMENTAL
Intervention: Euhydrated without dousing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypohydrated without dousing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Euhydrated with dousing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypohydrated with dousing
Number of subjects: 12
Study: 32423463

Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration concept involving GPs in regional teams with on-call schedules, pre-weekend visits, joint meetings, documentation, and improved medication safety.
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control group receives treatment as usual.
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1600
Study: 34807347

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 ug/day orally for 6 months in ND group
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 ug/day orally for 6 months in HD group
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 ug/day orally for 6 months in PD group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation) in ND group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation) in HD group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation) in PD group
Number of subjects: 134
Study: 34168105

Group type: EXPERIMENTAL
Intervention: Rivaroxaban for 9 consecutive months
Number of subjects: 1
Study: 32314521

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 867
Study: 36157118

Group type: EXPERIMENTAL
Intervention: Anti-bacterial antibody responses in CD patients
Number of subjects: 300

Group type: COMPARATOR
Intervention: Anti-bacterial antibody responses in healthy controls
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Biomarker panels
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Subgroup analysis
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 300
Study: 34437752

Group type: EXPERIMENTAL
Intervention: REGN1908-1909 (600 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: REGN1908-1909 (150 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: REGN1908-1909 (300 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: REGN1908-1909
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 36272526

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with cisplatin+vinorelbine
Number of subjects: 234

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 234
Study: 34327047

Group type: EXPERIMENTAL
Intervention: Nonpharmacological interventions for POTS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions for POTS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-line therapies for POTS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line therapies for POTS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-line therapies for POTS
Number of subjects: 0
Study: 35261056

Group type: EXPERIMENTAL
Intervention: 39-item checklist
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1-item OSATS GRS
Number of subjects: 26
Study: 33219603

Group type: EXPERIMENTAL
Intervention: Racial microaggressions
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 140
Study: 35722165

Group type: EXPERIMENTAL
Intervention: Ganduqing granules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32993879

Group type: EXPERIMENTAL
Intervention: Ultra‐lose dose imaging protocol (ULDP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard low‐dose imaging protocol (LDP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both ULDP and LDP
Number of subjects: 23
Study: 35286358

Group type: EXPERIMENTAL
Intervention: Rotation every 3 minutes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rotation every 5 minutes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rotation every 10 minutes
Number of subjects: 51
Study: 32329435

Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Actigraphic measurement
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Actigraphic activity levels
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Self-reported seasonality
Number of subjects: 103
Study: 35218300

Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART) offered through trial clinics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard national guidelines for ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate ART for PLHIV aware of their status but not on ART
Number of subjects: 0
Study: 32820139

Group type: EXPERIMENTAL
Intervention: BFR + exercise
Number of subjects: 46

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 46
Study: 36039949

Group type: EXPERIMENTAL
Intervention: Voclosporin (23.7 mg twice daily)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Voclosporin
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control
Number of subjects: 534
Study: 33221932

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (75–125 mg) in non-taper group
Number of subjects: 50

Group type: COMPARATOR
Intervention: MDMA-assisted psychotherapy (75–125 mg) in taper group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy (75–125 mg)
Number of subjects: 50
Study: 35433441

Group type: EXPERIMENTAL
Intervention: Geriatric assessment summary and GA-guided management recommendations
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (no summary or recommendations)
Number of subjects: 180
Study: 32152513

Group type: EXPERIMENTAL
Intervention: Egg condition (2 eggs/day for 6 days/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-Egg condition (energy-matched, non-egg, higher-CHO foods)
Number of subjects: 30
Study: 34488652

Group type: EXPERIMENTAL
Intervention: Follow-up with primary care provider after discharge
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Role of primary care provider in coordinating care
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Timing of follow-up visits
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Link between post-discharge visit and hospital readmissions
Number of subjects: 16
Study: 35726101

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injections (group 2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Blind injections (group 1)
Number of subjects: 71
Study: 34618724

Group type: EXPERIMENTAL
Intervention: Enhanced training incorporating components of the IMB model
Number of subjects: 5672

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 5672
Study: 32562440

Group type: EXPERIMENTAL
Intervention: New Donor Educational Materials (DnEM)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Current Donor Educational Materials (DnEM)
Number of subjects: 165